Welcome to the Satchi-Fainaro Laboratory
Combining multidisciplinary basic, translational and clinical approaches for cancer therapy
In our lab, we invest multidisciplinary efforts to elucidate the basic molecular mechanisms responsible for cancer progression to an aggressive, metastatic, drug-resistant phenotype in order to reveal new “druggable targets” for clinical translation. To achieve this goal, we exploit a rich platform of cell lines, ex vivo 3D models and in vivo mouse models of cancer as well as fresh and archived tissue specimens obtained from fruitful collaborations with several of TAU’s affiliated hospitals. We use a range of molecular and functional techniques to identify and validate new markers and drivers of cancer progression. The newly-gained knowledge is harnessed for the design of novel clinically-relevant polymer-based diagnostic and therapeutic tools for cancer. Our vision is that our multidisciplinary approach will revolutionize our perception of tumor progression and consequently the way we diagnose and treat cancer.
Photo by: Eric Sultan (Lady Globes)
Ronit Satchi-Fainaro, Ph.D.
Head, Cancer Research and Nanomedicine Laboratory
Kurt and Herman Lion Chair in Nanosciences and Nanotechnologies
Head of the TAU Kahn 3D Printing Initiative
The future is here
Watch the Satchi-Fainaro Lab on Ben-Shani's show, Kan 11
news and events
One of the seven collaborations between architects and biologists. Architectural Speculation: Urban Angiogenesis, Knafo Klimor Architects & Prof. Ronit Satchi-Fainaro, 2016.
“Nano GPS for personalized theranostics” – a lecture (in Hebrew) given as a part the Tel Aviv University event on the “White Night” that took place at Tel Aviv Port.
Our new paper on sulfonated amphiphilic siRNA nanocarrier for the treatment of glioblastoma is out
Sulfonated Amphiphilic Poly(α)glutamate Amine-A Potential siRNA Nanocarrier for the Treatment of Both Chemo-Sensitive and Chemo-Resistant Glioblastoma Tumors
Dec 2021 | Pharmaceutics
Microengineered perfusable 3D-bioprinted glioblastoma model for in vivo mimicry of tumor microenvironment
Aug 2021 | Science Advances
P-selectin inhibition alters microglia immunophenotype and blocks glioblastoma progression
March 2021 | Nature Communications